Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
Inv. presentation
Acq. completed
Consulting agrmnt
Employment agrmnt
|
|
Theriva Biologics, Inc. (SYN)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/03/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
| 08/11/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 08/08/2023 |
8-K
| Quarterly results |
| 08/02/2023 |
8-K
| Quarterly results |
| 05/11/2023 |
8-K
| Quarterly results |
| 03/30/2023 |
8-K
| Quarterly results |
| 03/10/2023 |
8-K
| Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Other Events, F... |
| 01/17/2023 |
8-K
| Quarterly results |
| 01/09/2023 |
8-K
| Quarterly results |
| 12/23/2022 |
8-K
| Quarterly results |
| 12/20/2022 |
8-K
| Quarterly results |
| 10/12/2022 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial S... |
| 10/03/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 09/30/2022 |
8-K
| Quarterly results |
| 09/27/2022 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 09/12/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 09/06/2022 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 08/11/2022 |
8-K
| Quarterly results |
| 08/03/2022 |
8-K
| Quarterly results |
| 07/29/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu...|
Docs:
|
"SYNTHETIC BIOLOGICS, INC. CERTIFICATE OF DESIGNATION OF SERIES C CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 78.1955 OF THE NEVADA REVISED STATUTES The following is a statement of the voting powers, designations, preferences, limitations, restrictions and relative rights of “Series C Convertible Preferred Stock” of Synthetic Biologics, Inc., a Nevada corporation , as established by resolutions of the Corporation’ s Board of Directors pursuant to Nevada Revised Statutes 78.1955: WHEREAS, the Articles of Incorporation of the Corporation, as amended , provides for a class of its authorized stock known as preferred stock, consisting of 10,000,000 shares, $0.001 par value per share, issuable from time to time in one or more series; WHEREAS, the Board of Directors is authorized by resolution...",
"SYNTHETIC BIOLOGICS, INC. CERTIFICATE OF DESIGNATION OF SERIES D CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 78.1955 OF THE NEVADA REVISED STATUTES The following is a statement of the voting powers, designations, preferences, limitations, restrictions and relative rights of “Series D Convertible Preferred Stock” of Synthetic Biologics, Inc., a Nevada corporation , as established by resolutions of the Corporation’ s Board of Directors pursuant to Nevada Revised Statutes 78.1955: WHEREAS, the Articles of Incorporation of the Corporation, as amended , provides for a class of its authorized stock known as preferred stock, consisting of 10,000,000 shares, $0.001 par value per share, issuable from time to time in one or more series; WHEREAS, the Board of Directors is authorized by resolution...",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of July 28, 2022, between Synthetic Biologics, Inc., a Nevada corporation , and MSD Credit Opportunity Master Fund, L.P. . RECITALS A. The Company and the Purchaser are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4 of the Securities Act of 1933, as amended , and/or Rule 506 of Regulation D as promulgated by the United States Securities and Exchange Commission under the Securities Act; and B. The Purchaser wishes to purchase from the Company, and the Company wishes to sell and issue to the Purchaser, upon the terms and subject to the conditions stated in this Agreement, shares of the Company’ s preferred stock, par value $0.001 per share , ...",
"Synthetic Biologics Announces $3 Million Private Placement of Convertible Preferred Stock" |
|
| 07/25/2022 |
8-K
| Quarterly results |
| 07/15/2022 |
8-K
| Quarterly results |
| 07/14/2022 |
8-K
| Quarterly results |
| 05/16/2022 |
8-K
| Quarterly results |
| 05/16/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
8-K
| Quarterly results |
| 03/23/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/16/2022 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 03/11/2022 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity ... |
| 01/27/2022 |
8-K
| Investor presentation |
| 01/04/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/27/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/14/2021 |
8-K
| Quarterly results |
| 12/14/2021 |
8-K
| Quarterly results |
|
|
|